IntegraGen Appoints Jorg Leenings as Head of Sales and Marketing of its German Competence Centre for Genetic Diabetes Testing

IntegraGen, the personalized healthcare company focused
on the development and delivery of genetic tests for complex diseases
announced today the appointment of Jorg Leenings as Head of Sales and
Marketing for its Competence Centre for MODY (Maturity Onset Diabetes
of the Young) diabetes and other genetic causes of diabetes, in Bonn,
Germany.
A German native, Jorg Leenings brings more than 20 years of
experience in commercial diagnostic companies, most notably as Group
Product Manager and Sales & Marketing manager at BIO-RAD Laboratories
GmbH in Munich. Jorg spent nearly 15 years at BIO-RAD and was
previously at ABBOTT GmbH for 6 years. Jorg also worked as a
consultant, coordinating clinical studies for new products to achieve
CE certification and FDA approval. He received his diploma in Chemical
Engineering from Aachen University of Applied Sciences.
Welcoming Jorg Leenings in his new position, Dr Jan Mous,
President and CEO of IntegraGen said:
"Jorg has broad experience in the commercialization of diagnostic
products and I am sure that he will make a significant and valuable
contribution to our company. We are delighted to welcome him on
board."

Commenting on his new role at IntegraGen, Jorg Leenings added:

"I am very excited by the opportunity of heading IntegraGen's
first Competence Centre for diabetes testing in Germany. This is one
of the prime centres of its kind in Europe, providing expertise in
both MODY testing and other genetic causes of diabetes together with
expert analysis and genetic counselling."
IntegraGen is focused on the development of diagnostic and
prognostic genetic tests for complex diseases using its novel
technology platform for gene identification (Genome HIP(TM)). In 2005,
IntegraGen completed a EUR 8 million financing that is being used to
further develop the Company's genetic tests and to launch them into
the market. The company anticipates launching further genetic tests
for late onset type 2 diabetes in 2008.

Notes to editors:

About IntegraGen

IntegraGen SA uses its unique genomic analysis expertise to
identify genes associated with complex diseases and to develop
diagnostic and predictive genetic tests. The Company applies its
innovative gene mapping technology, GenomeHIP(R) (Genome Hybrid
Identity Profiling), to rapidly discover genetic loci that are
implicated in complex, multi-factorial diseases. GenomeHIP(R) is a
major advance that overcomes the limitations of existing marker based
familial linkage study methods.
IntegraGen is applying its discoveries to develop a series of
innovative IntegraTests(TM) and is poised to become a leader in the
rapidly growing field of predictive medicine. The Company will be a
fully integrated provider of genetic tests that can be used to
predict, prevent, diagnose and tailor personalized treatments for
complex diseases. Testing will be provided as a service through Expert
Centers, which will also provide expert analysis and genetic
counseling from an accredited MD-geneticist. The Company's first
Expert Center was established in 2005 in Bonn, Germany, to provide the
Company's first testing service for MODY diabetes (Mature Onset
Diabetes of the Young). The Company's strategy is to develop molecular
diagnostic tools for selected disease areas with high medical need.
IntegraGen's in-house programs are focused on specific neurological
disorders, like autism and bi-polar disorder, and metabolic disorders,
such as obesity and type 2 diabetes mellitus.
Founded in July 2000, IntegraGen has 34 employees and is based in
the French Genopole of Evry, near Paris, France, and in Bonn, Germany.
More information can be found at www.integragen.com

About MODY

Maturity Onset Diabetes of the Young (MODY) is an unusual type of
diabetes accounting for up to 5% of all diabetes (Type 1 and 2
compounded) worldwide. It is characterized by an early onset of
symptoms, typically under the age of 25 in patients with family
histories of the disease. Early detection and diagnosis is key to
preventing the debilitating side effects of diabetes such as
nephropathies, retinopathies and neuropathies.